Nuvectis Pharma, Inc. (NVCT)
Data as of , from SEC Form 4 filings.
See up to 3 months of NVCT. The 7-day demo opens the 1M and 3M ranges and puts NVCT on your watchlist.
Start 7-day demoLatest NVCT insider trades
About Nuvectis Pharma, Inc. (NVCT)
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.
- FORT LEE, NJ
- 13
- 2022
- Nasdaq
NVCT Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Grant or award | 1 | 30,000 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
NVCT insider transactions (Form 4)
2117 Form 4 filings on record, the earliest from Nov 8, 2024, newest first.
| Traded | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Michael J. Carson - Officer | Grant or award | Common Stock | 30,000 footnote F1 | $0.00 | - | |
| ||||||
| Marlio Charles Mosseri - 10% Owner | Open-market purchase | Common Stock | 50,000 | $18.32 footnote F1 | $916K | |
| ||||||
| Ron Bentsur - Officer | Open-market purchase | Common Stock | 12,500 footnote F1 | $20.00 | $250K | |
| ||||||
| Kenneth Hoberman - Director | Grant or award | Common Stock | 35,000 footnote F1 | $0.00 | - | |
| ||||||
| James F. Oliviero III - Director | Grant or award | Common Stock | 35,000 footnote F1 | $0.00 | - | |
| ||||||
 Juan Sanchez - Director | Grant or award | Common Stock | 35,000 footnote F1 | $0.00 | - | |
| ||||||
| Matthew L. Kaplan - Director | Grant or award | Common Stock | 35,000 footnote F1 | $0.00 | - | |
| ||||||
| Juan Sanchez - Director | Open-market purchase | Common Stock | 13,000 | $5.79 footnote F1 | $75K | |
| ||||||
| Matthew L. Kaplan - Director | Open-market purchase | Common Stock | 11,000 footnote F1 | $5.84 | $64K | |
| ||||||
| Ron Bentsur - Officer | Open-market purchase | Common Stock | 5,000 | $5.72 | $29K | |
| Juan Sanchez - Director | Grant or award | Common Stock | 30,000 footnote F1 | $0.00 | - | |
| ||||||
| Marlio Charles Mosseri - 10% Owner | Open-market purchase | Common Stock | 46,900 | $6.06 | $284K | |
| Marlio Charles Mosseri - 10% Owner | Open-market purchase | Common Stock | 35,034 | $6.15 | $215K | |
| Marlio Charles Mosseri - 10% Owner | Open-market purchase | Common Stock | 72,836 | $6.28 | $457K | |
| Ron Bentsur - Officer | Open-market purchase | Common Stock | 4,500 | $4.65 | $21K | |
| Marlio Charles Mosseri - 10% Owner | Open-market purchase | Common Stock | 17,000 | $4.70 | $80K | |
| Enrique Poradosu - Officer | Open-market purchase | Common Stock | 2,000 | $4.99 | $10K | |
| Ron Bentsur - Officer | Open-market purchase | Common Stock | 20,000 | $4.92 | $98K | |
| Michael J. Carson - Officer | Grant or award | Common Stock | 28,806 | $0.00 | - | |
| Michael J. Carson - Officer | Grant or award | Common Stock | 34,567 | $0.00 | - | |
| Michael J. Carson - Officer | Open-market sale | Common Stock | 2,755 | $8.16 | $22K | |
NVCT insider trading FAQ
What is the latest insider trade for NVCT?
Nuvectis Pharma, Inc. (NVCT) had 1 insider filing in the last 90 days, with the most recent on 5 August 2026. The full record for NVCT runs to 17 Form 4 filings, the earliest from 8 November 2024. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying NVCT stock?
No insider purchases of NVCT were filed in the last 90 days. 12 purchases are on record for this company.
How many insiders are selling NVCT stock?
No insider sales of NVCT were filed in the last 90 days. 1 sale is on record for this company.
Where can I see NVCT SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects NVCT Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Michael J. Carson view on EDGAR
- - Marlio Charles Mosseri view on EDGAR
- - Ron Bentsur view on EDGAR
- - Kenneth Hoberman view on EDGAR
- - James F. Oliviero III view on EDGAR
- - Juan Sanchez view on EDGAR
- - Matthew L. Kaplan view on EDGAR
- - Juan Sanchez view on EDGAR
- - Matthew L. Kaplan view on EDGAR
Related companies with recent insider activity
Learn more
- What the Form 4 transaction codes mean
- Grants, option exercises, gifts and tax withholding are not trades on the market. The codes say which is which.
- Insider activity in Health Care
- Where NVCT's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow NVCT with a 7-day demo
- NVCT on your watchlist
- Every NVCT Form 4 filing on record
- Up to 3 months of NVCT price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
